RVPH (RVPH)

Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a late-stage biopharma innovator targeting unmet needs in CNS, respiratory, inflammatory, and cardiometabolic disorders. Flagship candidate brilaroxazine (RP5063) advances Phase 3 trials for schizophrenia and bipolar disorder, with potential in ADHD, dementia psychosis, and pulmonary hypertension. Pipeline includes RP1208 for depression/obesity. Founded 2018, HQ in Cupertino, CA. Recent catalysts: 93% monthly stock surge amid trial momentum. High-risk/high-reward biotech play—monitor FDA milestones for explosive upside.